- Home
- BOOT vs RYTM Comparison
BOOT vs RYTM Comparison
Compare BOOT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOOT
- RYTM
- Stock Information
- Founded
- BOOT 1978
- RYTM 2008
- Country
- BOOT United States
- RYTM United States
- Employees
- BOOT N/A
- RYTM N/A
- Industry
- BOOT Clothing/Shoe/Accessory Stores
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- BOOT Consumer Discretionary
- RYTM Health Care
- Exchange
- BOOT Nasdaq
- RYTM Nasdaq
- Market Cap
- BOOT 5.7B
- RYTM 6.4B
- IPO Year
- BOOT 2014
- RYTM 2017
- Fundamental
- Price
- BOOT $174.70
- RYTM $100.16
- Analyst Decision
- BOOT Strong Buy
- RYTM Strong Buy
- Analyst Count
- BOOT 12
- RYTM 12
- Target Price
- BOOT $201.73
- RYTM $117.00
- AVG Volume (30 Days)
- BOOT 627.5K
- RYTM 677.8K
- Earning Date
- BOOT 10-29-2025
- RYTM 11-04-2025
- Dividend Yield
- BOOT N/A
- RYTM N/A
- EPS Growth
- BOOT 36.30
- RYTM N/A
- EPS
- BOOT 6.78
- RYTM N/A
- Revenue
- BOOT $2,071,382,000.00
- RYTM $174,334,000.00
- Revenue This Year
- BOOT $18.78
- RYTM $46.10
- Revenue Next Year
- BOOT $13.13
- RYTM $63.02
- P/E Ratio
- BOOT $25.52
- RYTM N/A
- Revenue Growth
- BOOT 17.82
- RYTM 54.92
- 52 Week Low
- BOOT $86.17
- RYTM $45.91
- 52 Week High
- BOOT $205.31
- RYTM $116.00
- Technical
- Relative Strength Index (RSI)
- BOOT 39.71
- RYTM 43.95
- Support Level
- BOOT $181.36
- RYTM $95.27
- Resistance Level
- BOOT $189.52
- RYTM $102.70
- Average True Range (ATR)
- BOOT 8.46
- RYTM 5.21
- MACD
- BOOT -2.20
- RYTM -1.50
- Stochastic Oscillator
- BOOT 2.53
- RYTM 21.97
About BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.